BNTX — BioNTech SE Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge CapSuper Stock
- $39.40bn
- $30.16bn
- €18.98bn
- 81
- 92
- 59
- 90
Annual cashflow statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2017 December 31st | C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -85.9 | -47.7 | -179 | -146 | 15,046 |
| Depreciation | |||||
| Non-Cash Items | 29.4 | 7.94 | 31.1 | 188 | -32.6 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.6 | -41.1 | -84.1 | -94.9 | -14,199 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -52.6 | -58.9 | -199 | -13.5 | 890 |
| Capital Expenditures | -57.7 | -67.2 | -71.1 | -85.4 | -154 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 5.19 | 0.705 | -6.04 | -59.4 | -412 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -52.5 | -66.5 | -77.1 | -145 | -566 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.64 | 365 | 383 | 895 | 94.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -132 | 239 | 108 | 691 | 483 |